Vanguard Group
ANIX icon

Vanguard Group’s Anixa Biosciences ANIX Stock Holding History

Vanguard Group’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.55M Buy
1,459,574
+37,232
+3% +$152K ﹤0.01% 3289
2025
Q3 		$4.69M Buy
1,422,342
+29,436
+2% +$93.1K ﹤0.01% 3301
2025
Q2 		$4.6M Hold
1,392,906
– – ﹤0.01% 3246
2025
Q1 		$3.98M Hold
1,392,906
– – ﹤0.01% 3264
2024
Q4 		$3.23M Hold
1,392,906
– – ﹤0.01% 3422
2024
Q3 		$4.39M Hold
1,392,906
– – ﹤0.01% 3315
2024
Q2 		$3.08M Hold
1,392,906
– – ﹤0.01% 3426
2024
Q1 		$4.35M Hold
1,392,906
– – ﹤0.01% 3350
2023
Q4 		$5.4M Buy
1,392,906
+29,984
+2% +$101K ﹤0.01% 3258
2023
Q3 		$4.46M Buy
1,362,922
+2,776
+0.2% +$9.71K ﹤0.01% 3302
2023
Q2 		$4.35M Buy
1,360,146
+21,969
+2% +$84.6K ﹤0.01% 3374
2023
Q1 		$5.75M Buy
1,338,177
+31,035
+2% +$136K ﹤0.01% 3234
2022
Q4 		$5.56M Buy
1,307,142
+7,144
+0.5% +$34.4K ﹤0.01% 3257
2022
Q3 		$6.4M Hold
1,299,998
– – ﹤0.01% 3185
2022
Q2 		$3.98M Hold
1,299,998
– – ﹤0.01% 3499
2022
Q1 		$3.56M Sell
1,299,998
-7,813
-0.6% -$22.9K ﹤0.01% 3688
2021
Q4 		$3.88M Buy
1,307,811
+2,880
+0.2% +$11.6K ﹤0.01% 3747
2021
Q3 		$6.22M Buy
1,304,931
+2,700
+0.2% +$12.2K ﹤0.01% 3517
2021
Q2 		$5.05M Buy
1,302,231
+22,360
+2% +$95.2K ﹤0.01% 3602
2021
Q1 		$5.99M Buy
1,279,871
+616,846
+93% +$2.95M ﹤0.01% 3432
2020
Q4 		$2.04M Buy
663,025
+6,147
+0.9% +$15.4K ﹤0.01% 3653
2020
Q3 		$1.6M Sell
656,878
-16,218
-2% -$41.8K ﹤0.01% 3549
2020
Q2 		$2.06M Buy
673,096
+4,070
+0.6% +$8.44K ﹤0.01% 3423
2020
Q1 		$1.06M Hold
669,026
– – ﹤0.01% 3469
2019
Q4 		$2.19M Buy
669,026
+153
+0% +$561 ﹤0.01% 3424
2019
Q3 		$2.68M Buy
668,873
+27,400
+4% +$115K ﹤0.01% 3355
2019
Q2 		$2.33M Hold
641,473
– – ﹤0.01% 3432
2019
Q1 		$2.9M Buy
641,473
+2,000
+0.3% +$9.53K ﹤0.01% 3342
2018
Q4 		$2.52M Buy
639,473
+61,227
+11% +$263K ﹤0.01% 3301
2018
Q3 		$2.68M Buy
578,246
+700
+0.1% +$2.64K ﹤0.01% 3435
2018
Q2 		$1.75M Buy
577,546
+3,922
+0.7% +$14.5K ﹤0.01% 3539
2018
Q1 		$2.2M Sell
573,624
-158,809
-22% -$611K ﹤0.01% 3427
2017
Q4 		$1.73M Buy
732,433
+358,320
+96% +$929K ﹤0.01% 3471
2017
Q3 		$984K Buy
374,113
+359,933
+2,538% +$396K ﹤0.01% 3594
2017
Q2 		$16K Sell
14,180
-1
-0% -$1 ﹤0.01% 4064
2017
Q1 		$42K Buy
14,181
+1,500
+12% +$6.45K ﹤0.01% 4036
2016
Q4 		$68K Buy
+12,681
New +$70.4K ﹤0.01% 4005

Other funds holding ANIX

LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Vanguard Group's ANIX Position: Q4 2025 in Review

Vanguard Group increased its Anixa Biosciences (ANIX) stake by 2.6% in Q4 2025, buying an estimated $152K and bringing the position to 1,459,574 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

Vanguard Group first reported a position in ANIX in Q4 2016 and has held it in 37 quarters since. The position peaked at $6.4M in Q3 2022. 71 funds tracked by Wall St. Rank hold ANIX as of Q4 2025.

  • Vanguard Group held 1,459,574 shares of Anixa Biosciences worth $4.55M as of Q4 2025.
  • Vanguard Group bought 37,232 Anixa Biosciences shares in Q4 2025, an estimated $152K.
  • Anixa Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3289 holding.
  • Vanguard Group first reported a position in Anixa Biosciences in Q4 2016 and has held it in 37 quarters since.
  • Vanguard Group's Anixa Biosciences position peaked at $6.4M in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.